A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

ClinicalTrials.gov ID: NCT02714218

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02714218. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

Study identification

NCT ID: NCT02714218
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 387 participants

Conditions and interventions

Conditions

Melanoma

Interventions

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 4, 2016 (Actual)
Primary completion: Apr 20, 2017 (Actual)
Completion: May 28, 2021 (Actual)
Last update posted: Jun 24, 2022

2016 – 2021

United States locations

U.S. sites: 11
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
University Of Colorado Cancer Center	Aurora	Colorado	80045	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33612	—
Allina Health	Fridley	Minnesota	55432	—
Washington University School Of Medicine	St Louis	Missouri	63110	—
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89148	—
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Levine Cancer Institute	Charlotte	North Carolina	28204	—
Lehigh Valley Health Network	Allentown	Pennsylvania	18103	—
University Of Virginia Health System	Charlottesville	Virginia	22908	—
University of Washington - Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02714218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 24, 2022 · Synced Nov 13, 2026